Éva Remenár

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

Jan B. Vermorken, Éva Remenár, Carla van Herpen et al. · New England Journal of Medicine · 2007 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár et al. · JAMA Oncology · 2018 · 310 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno et al. · European Journal of Cancer · 2018 · 267 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17